The stock of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) hit a new 52-week low and has $3.12 target or 10.00% below today’s $3.47 share price. The 7 months bearish chart indicates high risk for the $38.21M company. The 1-year low was reported on Oct, 31 by Barchart.com. If the $3.12 price target is reached, the company will be worth $3.82 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 22,961 shares traded hands. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has declined 22.80% since March 29, 2016 and is downtrending. It has underperformed by 26.27% the S&P500.
Analysts await Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to report earnings on November, 14. They expect $-0.38 EPS, down 65.22% or $0.15 from last year’s $-0.23 per share. After $-0.39 actual EPS reported by Galmed Pharmaceuticals Ltd for the previous quarter, Wall Street now forecasts -2.56% EPS growth.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Ratings Coverage
Out of 2 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Galmed Pharmaceuticals Ltd has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Roth Capital given on Thursday, August 13. On Monday, March 28 the stock rating was reinitiated by H.C. Wainwright with “Buy”.
According to Zacks Investment Research, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.”
More notable recent Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) news were published by: Prnewswire.com which released: “Galmed Pharmaceuticals Third Quarter 2016 Conference Call and Webcast …” on October 31, 2016, also Prnewswire.com with their article: “Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the …” published on July 28, 2016, Prnewswire.com published: “Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D …” on September 08, 2016. More interesting news about Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) were released by: Prnewswire.com and their article: “Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 03, 2016 as well as Prnewswire.com‘s news article titled: “Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D …” with publication date: August 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.